# Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System Clinical Study

Study · id `cardio:ct-nct03284255` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03284255](<https://clinicaltrials.gov/study/NCT03284255>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03284255

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 431 participants.

## Technical summary

Registry record NCT03284255. Randomized; no masking; primary purpose treatment. Start 2017-09-11 (actual); primary completion 2020-08-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 431 participants (enrolled count; ClinicalTrials.gov record NCT03284255, source copy `cardio:ctgov-nct03284255-2019-11-21`, retrieved 2026-10-26)
- Started: 2017-09-11 (actual) (ClinicalTrials.gov record NCT03284255, source copy `cardio:ctgov-nct03284255-2019-11-21`, retrieved 2026-10-26)
- Primary completion: 2020-08-30 (anticipated) (ClinicalTrials.gov record NCT03284255, source copy `cardio:ctgov-nct03284255-2019-11-21`, retrieved 2026-10-26)
- Completion: 2024-08-30 (anticipated) (ClinicalTrials.gov record NCT03284255, source copy `cardio:ctgov-nct03284255-2019-11-21`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03284255, source copy `cardio:ctgov-nct03284255-2019-11-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03284255-2019-11-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System Clinical Study
- Condition: Coronary Artery Disease
- Condition: Antineoplastic Agents
- Intervention (Device): study group
- Intervention (Device): control group
- Lead sponsor: Shanghai Bio-heart Biological Technology Co., Ltd.
- Lead sponsor class: INDUSTRY
- Collaborator: CCRF Inc., Beijing, China
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as a collaborator: CCRF Inc., Beijing, China (`cardio:org-ccrf-inc-beijing-china`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: A Randomized Comparison of Bioheart Sirolimus-Eluting Bioresorbable Scaffold and Everolimus-Eluting Stents: The BIOHEART-II Trial (`cardio:pubmed-39814492`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: fa569cdb0775b0388507abd0027d70d202b1179e94b06079bd6b4b9034af260a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
